Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. METHODS: This is an open-label retrospective...

Full description

Bibliographic Details
Main Authors: Tamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, Dorothee Chabas, Elizabeth Crabtree-Hartman, Bruce A Cree, Douglas S Goodin, Ari J Green, Darin T Okuda, Daniel Pelletier, Scott S Zamvil, Eric Vittinghoff, Emmanuelle Waubant
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3033401?pdf=render

Internet

http://europepmc.org/articles/PMC3033401?pdf=render

Similar Items